Connect with us

Government

Three Leisure Stocks to Buy as People Increasingly Travel and Fly

Three leisure stocks to buy as people increasingly travel and fly feature a giant amusement park and entertainment giant that just lured back an esteemed…

Published

on

Three leisure stocks to buy as people increasingly travel and fly feature a giant amusement park and entertainment giant that just lured back an esteemed former chief, an aquatic entertainment company and global mountain resort operator.

Increased energy costs and a shift toward leisure spending have become trends that should continue in the months ahead, according to BofA Global Research. Pent-up interest in leisure as the economy grows and employment remains high could propel each of these companies that endured the fallout of a global pandemic from the 2020 until now.

However, aggregated BC credit and debit card data, total card spending slowed in September across goods categories, and spending on leisure services was flat, which may signal the reopening tailwinds on discretionary services are fading, according to BofA. The BofA US Economics team expects a recession, accompanied by a labor market slowdown and further weakness in consumer spending during first-quarter 2023.

Return of Bob Iger to Lead Disney Lifts One of Three Leisure Stocks to Buy

Walt Disney Co., (NYSE: DIS), a Burbank, California-based media and entertainment company, enticed Robert A. Iger, its former chief executive officer, to return to that role effective Sunday night, Nov. 20. Iger, who spent more than four decades at the company, including 15 years at the helm, agreed to serve as Disney’s CEO for two additional years, accepting a mandate from the board of directors to set the strategic direction for renewed growth and to develop a successor to lead the company at the completion of his term.

Iger replaces Bob Chapek, his hand-picked successor, who stepped down from his position in a surprise move. BofA wrote a research report that rated Disney a buy and gave the company a $115 price objective that offers roughly 25% upside from current levels. Iger is expected to fully re-evaluate several of the recent strategic initiatives and corporate restructurings.

The company’s share price had been trending down for the past year but perked up after news spread about Iger’s return.

Chart courtesy of www.stockcharts.com

Successor Struggled Amid COVID Crisis and Political Fallout Due to Controversial Content

Chapek, who took over the helm at Disney in February 2020, incurred concurrent crises shortly after he began that included the COVID-19 pandemic, significant management turnover and several public relations missteps, such as contract disputes with talent and a public battle with the governor of Florida about the company’s content. The leadership change comes on the heels of “disappointing” results in the company’s latest quarter, BofA wrote.

“To Chapek’s credit, he oversaw several transformational changes in Theme Parks, which drove a healthy recovery in revenue and operating profit exiting the pandemic,” BofA reported. “Chapek also took over as CEO during a very challenging time for the industry as it managed the transition toward streaming.”

Despite Iger’s track record and experience at the company and industry, he is expected to fully re-evaluate several recent strategic initiatives and corporate restructurings since his departure. As a result, investors should expect some near-term uncertainty about the company’s direction.

Iger Could Rejuvenate Disney as One of Three Leisure Stocks to Buy

Iger’s first priority likely will be to articulate his strategic priorities for Disney, BofA wrote. Several of Chapek’s recent initiatives and restructurings will be reviewed. They include a move to restructure the company’s Media and Entertainment Distribution segment to centralize budgetary power for content and distribution, as well as raise prices in Theme Parks and DIS+.

“Iger has made public comments recently on the secular challenges in the linear TV ecosystem, which, coupled with accelerating linear subscriber declines, could signal a potential openness to reevaluate strategic alternatives,” BofA wrote. “We also would not be surprised if this announcement prompts another wave of management turnover.”

Near-term catalysts for Disney could include any update on the strategic direction of the company, continued robust theme park demand with several levers for future growth, price increases for Disney+ and Hulu, the roll-out Disney+’s ad-supported tier on Dec. 8 and possible sports betting at ESPN, BofA forecast.

SeaWorld Jumps Among Three Leisure Stocks to Buy

Mark Skousen, who leads the Forecasts & Strategies investment newsletter and advisory services that include Home Run Trader, recommends SeaWorld Entertainment (NYSE: SEAS), of Orlando, Florida. The theme park and entertainment company is a “big beneficiary” of the new post-pandemic economy, he added.

Mark Skousen, Forecasts & Strategies chief and Ben Franklin scion, meets Paul Dykewicz.

SeaWorld’s revenue hit $1.7 billion over the last 12 months, while its third-quarter earnings jumped 32% on an 8.4% increase in sales. Plus, shares of SeaWorld have soared nearly 300% over the past five years, despite the pandemic, Skousen said.

With the lockdowns over and consumers choosing to spend more on experiential services, the outlook for SeaWorld is exceptional, Skousen recently wrote to his Home Run Trader subscribers.

Chart courtesy of www.stockcharts.com

Insider Buying Boosts the Second of Three Leisure Stocks to Buy

SeaWorld’s Treasurer and Chief Financial Officer Michelle Adams recently purchased 39,000 shares at $51.03, an investment of nearly $2 million. She now owns more than 75,000 shares.

In addition, Chief Commercial Officer Christopher Finazzo purchased 8,950 shares a couple weeks later. He owns over 72,000 shares.

These are “two savvy insiders,” Skousen wrote to his subscribers. He advised that they own the stock, too.

Another reason Skousen said he likes SeaWorld is that his daughter Hayley, a professional figure skater, is performing in a principal role in SeaWorld’s Christmas Celebration in Orlando, Florida. She provided the following link that shows her doing a backflip. Her husband, Pablo, also works there as a musician.

The company’s recognized brands include SeaWorld, Busch Gardens and Sea Rescue. The latter unit saves and rehabilitates marine animals that are ill, injured or abandoned, with the goal of returning them to the wild.

During SeaWorld’s 50-year history, it has built 12 destination and regional theme parks in key markets across the United States, hosting an average of more than 20 million visitors a year.

SeaWorld Shines as One of Three Leisure Stocks to Buy

Guests to SeaWorld attractions receive a variety of up-close experiences with wildlife, as well as thrill rides and shows. Unlike the controversy Disney has encountered, SeaWorld has produced Parent’s Choice and Emmy-Award-winning shows like Sea Rescue and The Wildlife Docs that celebrate the natural world.

“The pandemic was a big negative for entertainment parks, of course, as they were forced to shut down,” Skousen wrote to his subscribers. “But most of them are coming back in a big way. And SeaWorld is no exception.”

Revenue hit $1.67 billion over the last 12 months and sales are up 15% year-over-year, Skousen noted. With the pandemic receding, the outlook remains positive, he added.

Skousen not only recommended the stock, but call options, too. His Home Run Trader service offers both ways to profit.

Vail Resorts Joins Three Leisure Stocks to Buy

Another BofA recommendation that also is favored by the Baron Funds is Vail Resorts (NYSE: MTN), of Broomfield, Colorado. Vail’s focus includes using data to drive a unique, advanced customer commitment for a recurring business model. MTN is also well positioned to benefit from high-end, pent-up leisure demand in the coming ski season.

One shareholder of Vail Resorts is the Baron Growth Fund (BGRFX). BofA rates Vail Resorts as a buy, as does Michelle Connell, the chief executive officer of Portia Capital Management, of Dallas, Texas.

Michelle Connell heads Portia Capital Management, of Dallas, Texas.

Connell’s key reasons for investing in MTN include:

  • Strong growing revenues in a softening economy. Despite MTN increasing ticket prices 7.5%, the company’s revenue from ski passes was already up 7% year through the end of September 2022.
  • $320 Million Invested for Improved Consumer Experience. Just in time for the 2022-23 ski season, MTN has invested $320 million to install 19 new chair lifts across 14 of its resorts.
  • Investment in Data Infrastructure. MTN has also invested heavily so that the online experience of its consumers is smoother and faster.
  • MTN should appeal to the environmentally conscious young investor who also skis. The company is ahead of schedule to meet its target of 2030 to have a zero net (carbon) operating footprint.
  • Estimated 12-month upside for MTN: 15-25%.

Chart courtesy of www.stockcharts.com

Vail Resorts has a long history in the ski industry, starting with the opening of Vail Mountain in 1962. It now has 37 resorts in 15 states and three countries, including some of the world’s most iconic destinations, as well as travel-centric retail and hospitality businesses.

The company’s subsidiaries operate destination mountain resorts and regional ski areas such as Beaver Creek, Breckenridge, Keystone and Crested Butte in Colorado; Park City in Utah; Heavenly, Northstar and Kirkwood in the Lake Tahoe area of California and Nevada; Whistler Blackcomb in British Columbia, Canada; Perisher, Falls Creek and Hotham in Australia; Stowe, Mount Snow, Okemo in Vermont; Hunter Mountain in New York; Mount Sunapee, Attitash, Wildcat and Crotched in New Hampshire; Stevens Pass in Washington; and Liberty, Roundtop, Whitetail, Jack Frost and Big Boulder in Pennsylvania. Vail Resorts owns and operates a variety of world-class luxury resorts for spa vacations or adventurous mountain lodges for relaxing after a day on the slopes.

Bivalent COVID-19 Vaccine Could Lift Leisure Activities Due to Enhanced Protection Against New Variant

The new bivalent COVID-19 booster provides superior protection against the omicron BA.5 variant, now the predominant strain of the virus. I received the new booster on Oct. 16 after it became available at pharmacies near my house.

However, 200-plus million Americans who are eligible have yet to accept the syringe of that new booster. New cases and deaths can hurt demand for leisure activities, so a bivalent booster could enhance both public health and the economy.

Cases in the country totaled 98,386,225 and deaths reached 1,077,020, as of Nov. 22. America has the dreaded distinction of amassing the most COVID-19 cases and deaths of any nation. Worldwide COVID-19 deaths totaled 6,623,547, as of Nov. 22, according to Johns Hopkins University. Global COVID-19 cases reached 638,978,541.

Roughly 80.6% of the U.S. population, or 267,476,279, have received at least one dose of a COVID-19 vaccine, as of Nov. 16, the CDC reported. People who obtained the primary COVID-19 doses totaled 228,154,832 of the U.S. population, or 68.7%, according to the CDC. The United States also has given a bivalent COVID-19 booster to 33,831,057 people who are age 18 and up, accounting for 13.1% of the U.S. population in that age range.

Despite Russia’s leaders calling their country’s attacks against Ukraine that began on Feb. 24 a “special military operation,” firing into Ukraine also killed two Polish civilians to further inflame an already volatile situation. Investors seeking ways to avoid losing money in the markets amid such uncertainty and escalation of violence should consider the

Bivalent COVID-19 Vaccine Gives Improved Protection Against New Variant

A new bivalent COVID-19 booster in the United States offers superior protection against the omicron BA.5 variant, now the predominant strain of the virus. I received the new booster on Oct. 16 after it became available at pharmacies not far from my house.

However, 200-plus million Americans who are eligible have yet to seize the opportunity. New cases and deaths can hurt demand for natural gas, so a bivalent booster that becomes widely used could aid both public health and the economy.

Cases in the country totaled 98,301,472 and deaths reached 1,077,020, as of Nov. 18. America has the dreaded distinction of amassing the most COVID-19 cases and deaths of any nation. Worldwide COVID-19 deaths totaled 6,619,779, as of Nov. 18, according to Johns Hopkins University. Global COVID-19 cases reached 637,577,338.

Roughly 80.6% of the U.S. population, or 267,476,279, have received at least one dose of a COVID-19 vaccine, as of Nov. 16, the CDC reported. People who obtained the primary COVID-19 doses totaled 228,154,832 of the U.S. population, or 68.7%, according to the CDC. The United States also has given a bivalent COVID-19 booster to 33,831,057 people who are age 18 and up, accounting for 13.1% of the U.S. population in that age range.

Despite Russia’s leaders calling their country’s attacks against Ukraine that began on Feb. 24 a “special military operation,” firing into Ukraine also killed two Polish civilians to further inflame an already volatile situation. Investors seeking ways to avoid losing money in the markets amid such uncertainty and escalation of violence should consider the

Bivalent COVID-19 Vaccine Gives Improved Protection Against New Variant

A new bivalent COVID-19 booster in the United States offers superior protection against the omicron BA.5 variant, now the predominant strain of the virus. I received the new booster on Oct. 16 after it became available at pharmacies not far from my house.

However, 200-plus million Americans who are eligible have yet to seize the opportunity. New cases and deaths can hurt demand for natural gas, so a bivalent booster that becomes widely used could aid both public health and the economy.

Cases in the United States totaled 98,386,225 and deaths reached 1,077,777, as of Nov. 12. America has the dreaded distinction of amassing the most COVID-19 cases and deaths of any nation. Worldwide COVID-19 deaths totaled 6,623,547, as of Nov. 22, according to Johns Hopkins University. Global COVID-19 cases reached 638,978,541.

Roughly 80.6% of the U.S. population, or 267,476,279, have received at least one dose of a COVID-19 vaccine, as of Nov. 16, the CDC reported. Those who obtained the primary COVID-19 doses totaled 228,154,832 of the U.S. population, or 68.7%, according to the CDC. The United States also has given a bivalent COVID-19 booster to 33,831,057 people who are age 18 and up, accounting for 13.1% of the U.S. population in that age range.

Despite Russia’s continued attacks against Ukraine that began on Feb. 24 as a so-called “special military operation,” people elsewhere still are able to enjoy leisure activities. Investors interested in a potentially good run may want to consider the three leisure stocks to buy as people increasingly travel and fly.

Paul Dykewicz, www.pauldykewicz.com, is an accomplished, award-winning journalist who has written for Dow Jones, the Wall Street JournalInvestor’s Business DailyUSA Today, the Journal of Commerce, Seeking Alpha, Guru Focus and other publications and websites. Paul, who can be followed on Twitter @PaulDykewicz, is the editor of StockInvestor.com and DividendInvestor.com, a writer for both websites and a columnist. He further is editorial director of Eagle Financial Publications in Washington, D.C., where he edits monthly investment newsletters, time-sensitive trading alerts, free e-letters and other investment reports. Paul previously served as business editor of Baltimore’s Daily Record newspaper. Special Holiday Offer: Paul is the author of an inspirational book, “Holy Smokes! Golden Guidance from Notre Dame’s Championship Chaplain,” with a foreword by former national championship-winning football coach Lou Holtz. The book is great holiday gift and is endorsed by Joe Montana, Joe Theismann, Ara Parseghian, “Rocket” Ismail, Reggie Brooks, Dick Vitale and many othersCall 202-677-4457 for special pricing on multiple-book purchases.

The post Three Leisure Stocks to Buy as People Increasingly Travel and Fly appeared first on Stock Investor.

Read More

Continue Reading

Spread & Containment

First-ever social responsibility report of Chinese enterprises in Saudi Arabia incorporates BGI Genomics projects

On December 1, 2022, the Social Responsibility Report of Chinese Companies in Saudi Arabia was officially launched, which is the first such report released…

Published

on

On December 1, 2022, the Social Responsibility Report of Chinese Companies in Saudi Arabia was officially launched, which is the first such report released by the Contact Office of Chinese Companies in Saudi Arabia. BGI Genomics projects in the Kingdom have been incorporated into this report.

Credit: BGI Genomics

On December 1, 2022, the Social Responsibility Report of Chinese Companies in Saudi Arabia was officially launched, which is the first such report released by the Contact Office of Chinese Companies in Saudi Arabia. BGI Genomics projects in the Kingdom have been incorporated into this report.

This event was attended by around 150 representatives of Chinese and Saudi enterprises, Saudi government officials, experts in the field of sustainable development, CCTV, Xinhua News Agency, Saudi Press Agency, Arab News and other media professionals. This Report presents the key projects and best practices of Chinese enterprises to fulfil their social and environmental responsibilities while advancing the Kingdom’s industry development.

Chen Weiqing, the Chinese ambassador to Saudi Arabia, said in his video speech that the Report highlighted Chinese enterprises’ best practices in serving the local community, safe production, green and low-carbon development and promoting local employment. The release of the Report helps Chinese enterprises in the Kingdom to strengthen communication with the local community, laying a stronger foundation for future collaboration.

Epidemic control and accelerating post-COVID 19 recovery

BGI Genomics has been fulfilling its corporate social responsibilities and worked with the Saudi people to fight the COVID-19 epidemic.

In March 2020, Saudi Arabia was hit by the pandemic. The Saudi government decided to adopt BGI Genomics’ Huo-Yan laboratory solution in April 2020. At the forefront of the fight against the epidemic, the company has built six laboratories in Riyadh, Makkah, Madinah, Dammam and Asir within two months, with a total area of nearly 5,000 square meters and a maximum daily testing throughput of 50,000 samples.

By the end of December 2021, BGI Genomics had sent 14 groups of experts, engineers and laboratory technicians to Saudi Arabia, amounting to over 700 people, and tested more than 16 million virus samples, accounting for more than half of the tests conducted during this period. The company has successfully trained over 400 qualified Saudi technicians, and all laboratories have been transferred to local authorities for the operation.

In the post-epidemic era, the Huo-Yan laboratories can continue to make positive contributions to public health, working with local medical institutions and the public health system to make breakthroughs in areas such as reproductive health, tumour prevention and control, and prevention.

Enhancing genomic technology localization and testing capabilities

In July 2022, BGI Almanahil and Tibbiyah Holdings, a wholly owned subsidiary of the Saudi Faisaliah Group, announced a joint venture (JV) to establish an integrated, trans-omics medical testing company specializing in genetic testing.

This JV company will help improve Saudi Arabia’s local clinical and public health testing and manufacturing capabilities, promote the localization of strategic products that have long been imported, contribute to the implementation and realization of the Kingdom’s Vision 2030 roadmap, and significantly enhance local capacity for third-party medical testing services as well as local production of critical medical supplies.

BGI Genomics attaches great importance to fulfilling its corporate social responsibility and has released its social responsibility report for four consecutive years since 2017. Since its establishment, the company has always been guided by the goal of enhancing health outcomes for all, relying on its autonomous multi-omics platform to accelerate technological innovation, promote reproductive health, strengthen tumour prevention and control, and accurately cure infections, and is committed to becoming a global leader in precision medicine and covering the entire public health industry chain.

The company will continue to work together with all stakeholders to contribute to the Kingdom’s Vision 2030 and the Belt and Road Initiative and looks forward to growing with our partners.

 

About BGI Genomics

BGI Genomics, headquartered in Shenzhen China, is the world’s leading integrated solutions provider of precision medicine. Our services cover over 100 countries and regions, involving more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.

 


Read More

Continue Reading

International

Alcohol deaths in the UK rose to record level in 2021

Nearly 10,000 people died from alcohol in 2021.

Published

on

By

Deaths from alcohol in the UK have risen to their highest level since records began in 2001, according to the latest data from the Office for National Statistics (ONS). In 2021, 9,641 people (14.8 per 100,000) died as a result of alcohol: a rise of 7.4% from 2020.

The leading cause of alcohol-specific deaths (deaths caused by diseases known to be a direct consequence of alcohol) continues to be liver disease. More than three-quarters (78%) of all alcohol deaths in 2021 were attributed to this cause. The remainder of the deaths were due to “mental and behavioural disorders because of the use of alcohol” and “accidental poisoning by, and exposure to, alcohol”.

Although there is no such thing as a safe level of drinking, and many people would feel the health benefits of reducing consumption, most of the risks of developing health problems and dying are skewed towards those who drink the most.

Between 2012 and 2019 alcohol-specific deaths remained relatively stable. It is no coincidence that deaths rose sharply during the first two years of the pandemic: those that were already drinking at harmful levels increased their consumption further during this period. Although liver disease can take years to develop, this process is accelerated when those drinking at harmful levels increase their consumption further.

Other statistics show that unplanned alcohol-related hospital admissions decreased during this period, which may have meant missed opportunities to provide help for those people experiencing problems with alcohol.

Looking beyond the headline figures, there are important differences in various groups within the population. Alcohol-specific deaths were not spread equally. For example, men were twice as likely to die as women. In 2021, 20.1 men per 100,000 died compared with 9.9 women.

Where you live in the UK matters, too, as deaths in Scotland are the highest, followed by Northern Ireland, Wales then and England – although the gap between the nations seems to be narrowing.

In England, deaths are highest in the north-east of England (20.4 per 100,000), which is twice as high as those in London (10.2 per 100,000). Although rates have increased in all regions; for example, there was a rise of 38% in south-west England from 2019 to 2021. This reflects what is already known about the relationship between deprivation and harm from alcohol. There is a two to fivefold higher risk of dying among lower-income groups compared with those from the higher-income groups.

Reflecting the growing trend of young people drinking less than older age groups, it is those aged 50 to 64 that account for most deaths due to liver disease. In 2021, for example, 39 people aged 25 to 29 died from alcohol-related liver disease, compared with 1,326 of those aged 50 to 59. This is related to a greater number of years of drinking but is also a general reflection that when older adults were younger, they tended to drink more than younger people do now.

Numbers of alcohol-specific deaths, by five-year age group and individual cause. Office for National Statistics – Alcohol-specific deaths in the UK: registered in 2021, National Records of Scotland and the Northern Ireland Statistics and Research Agency

Addressing harms

So what can be done to begin to address alcohol harms? It has been estimated that almost a quarter of drinkers in the UK drink above the recommended low-risk drinking guidelines. So this is a health and social issue that requires a national response. Low-impact initiatives, such as education and awareness raising, may not be enough.

The costs of alcohol to society are significant. A recent review estimated this to be £27 billion annually, with only half of this offset by tax revenue on alcohol products.

Timely access to specialist treatment can help to reduce the health risks associated with alcohol. Unfortunately, there have been significant cuts to funding for this type of intervention.

Around 80% of people classed as dependent on alcohol in England are not currently getting treatment support. While there has recently been extra funding for drug services to try and correct historic cuts, this has not been extended to alcohol. Reversing this by investing in services could help to reduce the rising number dying prematurely from alcohol.

A new strategy is long overdue

The last government strategy for alcohol was published in 2012, so there is a pressing need for a new one. This must address all the ways that the harms from alcohol can be tackled, from marketing and pricing to specialist treatment and recovery services.

A group, led by Liverpool MP Dan Carden, with cross-party support, recently called on the government to initiate an independent review of alcohol harm, along the lines of the review led by Dame Carol Black, which had a significant influence on drug policy and treatment funding.

Without such a review and strategy based on it, the harms caused by alcohol including premature death will continue to rise year after year. So much has changed since the last alcohol strategy in 2012 not least the current cost of living crisis. The outlook for investment in public health looks bleak, added to which this government doesn’t seem willing to curtail the efforts of the alcohol industry in marketing and protecting its products.

Harry Sumnall receives and has received funding from grant awarding bodies for alcohol and other drug research. He sits on grant-awarding funding panels, and is an unpaid scientific adviser to the MIND Foundation.

Ian Hamilton does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Read More

Continue Reading

Spread & Containment

Alcohol deaths in the UK rose to record levels in 2021

Nearly 10,000 people died from alcohol in 2021.

Published

on

By

There has been a record rise in deaths from alcohol in the UK, according to the latest data from the Office for National Statistics (ONS). In 2021, 9,641 people died as a result of alcohol: a rise of 7.4% from 2020.

The leading cause of alcohol-specific deaths (deaths caused by diseases known to be a direct consequence of alcohol) continues to be liver disease. More than three-quarters (78%) of all alcohol deaths in 2021 were attributed to this cause. The remainder of the deaths were due to “mental and behavioural disorders because of the use of alcohol” and “accidental poisoning by, and exposure to, alcohol”.

Although there is no such thing as a safe level of drinking, and many people would feel the health benefits of reducing consumption, most of the risks of developing health problems and dying are skewed towards those who drink the most.

Between 2012 and 2019 alcohol-specific deaths remained relatively stable. It is no coincidence that deaths rose sharply during the first two years of the pandemic: those that were already drinking at harmful levels increased their consumption further during this period. Although liver disease can take years to develop, this process is accelerated when those drinking at harmful levels increase their consumption further.

Other statistics show that unplanned alcohol-related hospital admissions decreased during this period, which may have meant missed opportunities to provide help for those people experiencing problems with alcohol.

Looking beyond the headline figures, there are important differences in various groups within the population. Alcohol-specific deaths were not spread equally. For example, men were twice as likely to die as women. In 2021, 20.1 men per 100,000 died compared with 9.9 women.

Where you live in the UK matters, too, as deaths in Scotland are the highest, followed by Northern Ireland, Wales then and England – although the gap between the nations seems to be narrowing.

In England, deaths are highest in the north-east of England (20.4 per 100,000), which is twice as high as those in London (10.2 per 100,000). Although rates have increased in all regions; for example, there was a rise of 38% in south-west England from 2019 to 2021. This reflects what is already known about the relationship between deprivation and harm from alcohol. There is a two to fivefold higher risk of dying among lower-income groups compared with those from the higher-income groups.

Reflecting the growing trend of young people drinking less than older age groups, it is those aged 50 to 64 that account for most deaths due to liver disease. In 2021, for example, 39 people aged 25 to 29 died from alcohol-related liver disease, compared with 1,326 of those aged 50 to 59. This is related to a greater number of years of drinking but is also a general reflection that when older adults were younger, they tended to drink more than younger people do now.

Numbers of alcohol-specific deaths, by five-year age group and individual cause. Office for National Statistics – Alcohol-specific deaths in the UK: registered in 2021, National Records of Scotland and the Northern Ireland Statistics and Research Agency

Addressing harms

So what can be done to begin to address alcohol harms? It has been estimated that almost a quarter of drinkers in the UK drink above the recommended low-risk drinking guidelines. So this is a health and social issue that requires a national response. Low-impact initiatives, such as education and awareness raising, may not be enough.

The costs of alcohol to society are significant. A recent review estimated this to be £27 billion annually, with only half of this offset by tax revenue on alcohol products.

Timely access to specialist treatment can help to reduce the health risks associated with alcohol. Unfortunately, there have been significant cuts to funding for this type of intervention.

Around 80% of people classed as dependent on alcohol in England are not currently getting treatment support. While there has recently been extra funding for drug services to try and correct historic cuts, this has not been extended to alcohol. Reversing this by investing in services could help to reduce the rising number dying prematurely from alcohol.

A new strategy is long overdue

The last government strategy for alcohol was published in 2012, so there is a pressing need for a new one. This must address all the ways that the harms from alcohol can be tackled, from marketing and pricing to specialist treatment and recovery services.

A group, led by Liverpool MP Dan Carden, with cross-party support, recently called on the government to initiate an independent review of alcohol harm, along the lines of the review led by Dame Carol Black, which had a significant influence on drug policy and treatment funding.

Without such a review and strategy based on it, the harms caused by alcohol including premature death will continue to rise year after year. So much has changed since the last alcohol strategy in 2012 not least the current cost of living crisis. The outlook for investment in public health looks bleak, added to which this government doesn’t seem willing to curtail the efforts of the alcohol industry in marketing and protecting its products.

Harry Sumnall receives and has received funding from grant awarding bodies for alcohol and other drug research. He sits on grant-awarding funding panels, and is an unpaid scientific adviser to the MIND Foundation.

Ian Hamilton does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Read More

Continue Reading

Trending